making money
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NPHC MONSTER MOVE IN PROGRESS!!!!!
$NPHC Massive red to green move in progress.
could see 004+ today
$NPHC MASSIVE RUNNER WE HAVE HERE! Going to be a very nice multi-day runner!!!!
New company tweet out!!! $RCHA
$RCHA Rich Pharmaceutical's Product Pipeline | Rich https://t.co/Yu5yiPHeST https://t.co/2XUXjDfso0 #acutemyeloidleukemia #AML pic.twitter.com/z770YkoFoJ
— Rich Pharmaceuticals (@RCHA_RichPharma) July 13, 2017
$RCHA about to have an awesome day today! very excited!!!
.25+ here we come $RCHA
Awesome week we are having $RCHA
8k out looking like an even bigger rest of the year we are about to have, this could very well be the next owcp going from subs to dollars.
$IMTV about to rock and roll!
$OTTV sitting solid. looking for a green close here.
yea bunch of weaklings being purged. $OTTV strong as an ox
$OTTV leaving sellers in the dust!!! will be a nice green close here today $OTTV
And also take note that everyone does what they want regardless of who says what.
$OTTV headed back up!!!
bouncing off middle bollie
looking very good here!!!!
$IMTV
$QEDN leaving teens!!!!
very stable now
$IMTV Heading north in a major way!!!
indeed
added a bunch more to my position this morning!!! and will continue adding!!! $IMTV
$IMTV Very nice update out with forward looking catalyst in the next week!!!
"We will be launching the complete, live version of the site on Friday July 7, 2017. As many of you have already seen on our corporate Twitter account (@ImaginationTVCo) the site is very dynamic and offers a multitude of new features specifically catering to the medical and recreational MJ communities."
http://www.otcmarkets.com/stock/IMTV/news/Imagination-TV--Inc--Shareholder-Update?id=163628&b=y
could very well happen very very soon....
sounds good to me. I'm always down to make another 6 figures.
Digging in even deeper tomorrow in the portfolio.
$IMTV pretty solid
yea I'm liking the communication and transparency. Looking good bro,
I'm Long!!!
$IMTV
Awesome close today, I'm expecting an even stronger day tomorrow!!!!
$IMTV
$EXAD STRONG AS AN OX!!! THIS WILL BE IN PENNYLAND SOON ENOUGH!!!
.014 MONDAY
looking good here $DTII
$DTII long and strong
$DTII HEADED TO MULTIPLE PENNIES AGAIN!!!!!
awesome stable run $DTII lets get her back to multiple pennies
$ARNH GOING CURRENT!!!
$SDVI LEAVING TRIPS TODAY GRAB YA TICKETS!!!!
company moving in a very good direction now, RS over and done with, time to move forward in life!
$RCHAD
$RCHAD RSI IS 41 EXTREMELY OVERSOLD, THERE'S SO MUCH ROOM TO RUN HERE IT'S MIND BOGGLING!!!
when 0009 falls We are in blue skies!!!
$RCHAD
$RCHAD Gearing up for a really strong move out the trips!!!
$RCHAD Gearing up for a really strong move out the trips!!!
HUGE indeed!!! $RCHAD
Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials
BEVERLY HILLS, CA - (NewMediaWire) - June 21, 2017 - Rich Pharmaceuticals, Inc. (OTC PINK: RCHA) ("Rich" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology announced today its principal doctor, Dr. Tontanai Numbenjapon, will commence clinical trials in Phramongkutklao Hospital in Thailand.
Dr. Numbenjapon specializes in medical oncology, hematology, and stem cell transplantation. He has over 14 years of experience in Hematology and Oncology.
"We are confident that Dr. Numbenjapon is the best and most qualified physician to head our research abroad, and look forward to his guidance as we embark on the next phase of our clinical studies," said Ben Chang, CEO.
Now that Rich Pharmaceuticals has filed an IND (
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology, with initial concentration in treating Acute Myelocytic Leukemia (AML), Hodgkin's Lymphoma (HL) and other blood related diseases. It is currently in Phase 1/2 clinical trials for the treatment of AML and HL. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. RP-323 is a phorbol ester, which induces differentiation and/or apoptosis in multiple cell lines and primary cells, activates protein kinase C (PKC), and modulates the activity of multiple downstream cell signaling pathways, including mitogen-activated protein kinase (MAPK) pathways. RP-323 induces PKC to produce NF kappa, which then produces NF kappa B that has the ability to regulate cellular responses by entering into the nucleus of cells. NF kappa B binds to DNA and changes the nature of the cell and (1) induces differentiation; (2) induces proliferation; (3) cytokine induction; (4) and/or apoptosis. Find out more at www.richpharmaceuticals.com
Forward-Looking Statements:
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to commence clinical trials and to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
$RCHAD received approval to start phase I/II with the FDA
nice news today
http://www.otcmarkets.com/stock/RCHAD/news
$RCHAD